The enzyme PARP1 helps repair single-stranded DNA breaks, and its inhibition shows antitumor efficacy in ovarian, breast, prostate and pancreatic cancers involving mutations in BRCA1 or BRCA2. However ...
Discover a study on PARP inhibitors in prostate cancer, revealing survival benefits for patients with BRCA1/2 alterations.
Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...
‘Animation companies are under pressure, being asked to do more with less each year.’ Enter Unreal Engine, Epic Games’ Rob Di Figlia argued at MipJunior In unveils, Di Figlia sneak-peeked a 90-second ...
A new drug combo is more effective in treating advanced prostate cancer The targeted drug niraparib added to hormone therapy slowed cancer growth and symptom progression Signs show the combo might ...
The clinical development of PARP inhibitors (PARPi) in prostate cancer has been driven by the recognition that alterations in DNA damage repair (DDR) genes — particularly homologous recombination ...
FRIDAY, Oct. 10, 2025 (HealthDay News) — A new drug combo is offering hope for men with advanced prostate cancer. Adding the targeted cancer drug niraparib to hormone therapy reduced the risk of ...
There are currently no FDA-approved treatments for CIAS, a disabling feature of the disease that includes impaired attention, memory, and executive function. The Food and Drug Administration (FDA) has ...
During a live event, Martin A. Martino, MD, analyzed overall survival outcomes from the PAOLA-1, SOLO-1, and PRIMA trials. Preventing relapse of advanced ovarian cancer with PARP inhibitors is now an ...
Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, ...
A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with specific genetic mutations, finds a major international trial led by UCL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback